other material
confidence high
sentiment positive
materiality 0.75
Rhythm posts positive PWS Phase 2 data; MC4R agonist results at ENDO 2026
RHYTHM PHARMACEUTICALS, INC.
- Interim Phase 2 PWS: 17 patients; mean BMI -3.06% at 6 months; 8/10 with moderate-severe hyperphagia improved ≥7 on HQ-CT.
- Setmelanotide in acquired HO: -18.9% mean BMI reduction after up to 2.5 years (n=11).
- Oral bivamelagon in HO: -16.6% BMI at 1 year for 600 mg dose (n=7).
- Real-world BBS: 62% of adults achieved ≥10% body weight loss at 12 months (n=286); reduced outpatient visits (p<0.05).
- Company plans Phase 3 development in PWS based on data.